Page last updated: 2024-11-12

resolvin e2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

resolvin E2: structure in first source; derivative of eicosapentaenoic acid in contrast to resolvin D that derives from docosahexaenoic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

resolvin E2 : A member of the class of resolvins that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid carrying two hydroxy substituents at positions 5 and 18 (the 5S,18R stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16061125
CHEMBL ID4168003
CHEBI ID81560
SCHEMBL ID144606
MeSH IDM0507004

Synonyms (15)

Synonym
5s,18r-dihydroxy-6e,8z,11z,14z,16e-eicosapentaenoic acid
C18173
resolvin e2
SCHEMBL144606
(5s,6e,8z,11z,14z,16e,18r)-5,18-dihydroxyicosa-6,8,11,14,16-pentaenoic acid
rve2
CHEBI:81560
LMFA03140011
865532-70-3
Q27155465
CHEMBL4168003
HY-133159
CS-0112552
resolvine2
AKOS040754895

Research Excerpts

Overview

Resolvin E2 is a potent anti-inflammatory compound. It is derived from eicosapentaenoic acid.

ExcerptReferenceRelevance
"Resolvin E2 is a potent anti-inflammatory compound, derived from eicosapentaenoic acid. "( Total synthesis and bioactivity of resolvin E2.
Arai, H; Arita, M; Inoue, M; Ogawa, S; Urabe, D; Yokokura, Y, 2009
)
2.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
resolvinHydroxy fatty acids that are di- or trihydroxy metabolites of the polyunsaturated omega-3 fatty acids, particularly icosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid.
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
secondary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to one other carbon and one hydrogen.
hydroxy polyunsaturated fatty acidAny polyunsaturated fatty acid carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Biosynthesis of specialized proresolving mediators (SPMs)13107
Biosynthesis of EPA-derived SPMs625
Biosynthesis of E-series 18(R)-resolvins413

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1357265Half life in air at 10 to 20 ug by HPLC analysis2018European journal of medicinal chemistry, Jun-10, Volume: 153Resolvins as proresolving inflammatory mediators in cardiovascular disease.
AID1548471Antiinflammatory activity against ip dosed BALB/c mouse model of heat-killed Propionibacterium acnes-induced peritonitis assessed as decrease in number of neutrophils administered 12 hrs post Propionibacterium acnes injection and measured after 12 hrs2020ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
Design and Synthesis of Benzene Congeners of Resolvin E2, a Proresolving Lipid Mediator, as Its Stable Equivalents.
AID1548470Antiinflammatory activity against BALB/c mouse model of heat-killed Propionibacterium acnes-induced peritonitis assessed as decrease in number of neutrophils at 300 pg, ip administered 12 hrs post Propionibacterium acnes injection and measured after 12 hr2020ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
Design and Synthesis of Benzene Congeners of Resolvin E2, a Proresolving Lipid Mediator, as Its Stable Equivalents.
AID1548472Metabolic stability in human liver microsomes assessed as parent compound remaining measured after 6 hrs by HPLC analysis2020ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
Design and Synthesis of Benzene Congeners of Resolvin E2, a Proresolving Lipid Mediator, as Its Stable Equivalents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (29.41)29.6817
2010's9 (52.94)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.03 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews3 (17.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]